Enlaza Therapeutics

Enlaza Therapeutics, with the slogan "Pioneering Covalent Biologics," is a pioneering company in the field of covalent biologics. The company, founded in 2020 and headquartered in the United States, is focused on developing novel classes of protein therapeutics to deliver more efficacious and safer treatments for patients. Their proprietary War-Lock™ platform leverages leading synthetic biology technology for site-specific covalent coupling driven by drug binding, enabling the development of a pipeline of first-in-class covalent biologics. At its latest funding round on 30 April 2024, Enlaza Therapeutics secured a significant $100.00M Series A investment from an impressive group of investors, including Lightspeed Venture Partners, Amgen Ventures, Avalon Ventures, Pappas Capital, Alexandria Venture Investments, Samsara BioCapital, J.P. Morgan Asset Management, Frazier Life Sciences, Regeneron, and Bregua. Enlaza Therapeutics' focus on pioneering technology and its strong investor backing position it as a compelling player in the Biopharma, Biotechnology, and Health Care industries, offering significant potential for growth and innovation in the biologics space.